Compensated Cirrhosis Clinical Trial
Official title:
The Natural History and Prognostic Factors of Compensated Cirrhosis: An Ambi Prospective Cohort Study
Study Design and Methodology - Study Population:Compensated Cirrhosis - Study Design: An Ambi Prospective Cohort study - Study Period: 2 Years - Sample size: Retrospective- All patients from Jan 2010 to Mar 2017 Prospective- Assuming the incidence of clinical decompensation is 5%/year.With alpha of 5%, power 80% we need to enroll 138 cases. Further assuming 20% drop out 166 cases will be enrolled. - Intervention: This is an observational study. No intervention will be given. Monitoring and assessment: All the routine investigation and clinical information will be collected at 6, 12,18 and 24 months.
Status | Recruiting |
Enrollment | 166 |
Est. completion date | January 2024 |
Est. primary completion date | January 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Age 18 to 75 years 2. Compensated cirrhosis 3. Biopsy proven cirrhosis or LSM > 12.5 Kpa. Exclusion Criteria: 1. Any current or prior clinical decompesnation (ascites, jaundice, encephalopathy or gastrointestinal hemorrhage). 2. Pregnant Women 3. Hepatocellular Carcinoma 4. Known case of severe cardiopulmonary disease 5. Known case of severe Hepato Pulmonary Syndrome |
Country | Name | City | State |
---|---|---|---|
India | Institute of Liver and Biliary Sciences | New Delhi | Delhi |
Lead Sponsor | Collaborator |
---|---|
Institute of Liver and Biliary Sciences, India |
India,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Development of ascites, jaundice, encephalopathy or gastrointestinal hemorrhage) during the follow up period of 2 yeas | 2 years | ||
Secondary | Patients with new onset/progression of esophageal varices during the period of 2 years | 2 years | ||
Secondary | Reduction in portal pressure with >20% from baseline at 6 months | 6 months | ||
Secondary | Reduction in portal pressure with >20% from baseline at 1 year | 1 year | ||
Secondary | Reduction in portal pressure with >20% from baseline at 2 year. | 2 year | ||
Secondary | Survival during the period of 2 years. | 2 years | ||
Secondary | Number of patients develop hepatocellular carcinoma (HCC) during follow up period 2 years. | 2 years | ||
Secondary | Number of patients develop Pulmonary Syndrome (HPS) during follow up period of 2 years. | 2 years | ||
Secondary | Number of patients develop Minimal Hepatic Encephalopathy (MHE) during follow up period of 2 years. | 2 years | ||
Secondary | Number of patients develop Hypersplenism during follow up period of 2 years. | 2 years | ||
Secondary | Number of patients develop Hepatic osteodystrophy during follow up period of 2 years. | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02207088 -
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
|
Phase 3 | |
Completed |
NCT02219503 -
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis
|
Phase 3 | |
Recruiting |
NCT04950764 -
An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI)
|
Phase 1 | |
Completed |
NCT05485714 -
Non-invasive Prediction of Esophageal Varices in Patients With Non-Alcoholic Fatty Liver Disease With Advanced Fibrosis
|
||
Enrolling by invitation |
NCT04160897 -
Risk of Hepatocellular Carcinoma in Patients Treated With ETV vs TDF for Chronic Hepatitis B With Compensated Cirrhosis
|
||
Completed |
NCT01704755 -
A Study to Evaluate the Safety and Efficacy of ABT-450/Ritonavir/ABT-267; (ABT-267 Also Known as Ombitasvir) and ABT-333 (Also Known as Dasabuvir) Coadministered With Ribavirin (RBV) in Hepatitis C Virus (HCV) Genotype 1-infected Adults With Compensated Cirrhosis
|
Phase 3 | |
Completed |
NCT01409356 -
Effects of Weight Loss on Portal Pressure in Patients With Overweight/Obesity and Cirrhosis
|
Phase 2 | |
Terminated |
NCT04060147 -
Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis
|
Phase 1 | |
Active, not recruiting |
NCT03749954 -
Detachable String Magnetically Controlled Capsule Endoscopy for Detecting High-risk Varices in Compensated Cirrhosis
|
||
Completed |
NCT01995071 -
A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)
|
Phase 2 | |
Not yet recruiting |
NCT02732405 -
Study to Investigate Tolerability and Efficacy of MK5172 / MK8742 Without Ribavirin for 12 Weeks in Patients With Chronic HCV G1b Infection With Compensated Cirrhosis
|
Phase 3 | |
Completed |
NCT04210245 -
Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)
|
Phase 2 | |
Completed |
NCT05367596 -
OPTIMIzing muScle Preservation in paTients wIth Cirrhosis
|
N/A | |
Recruiting |
NCT03990753 -
Microbiome/Peptidome-based Model for Non-invasive Detection of High-risk Gastroesophageal Varices in Compensated Cirrhosis (CHESS1901/APPHA1901)
|
||
Completed |
NCT00190385 -
Screening of Hepatocellular Carcinoma in Patients With Compensated Cirrhosis
|
Phase 3 | |
Recruiting |
NCT04196998 -
Three Types of Nucleotide/Nucleoside Analogues Therapy in Patients With Hepatitis b Virus Related Compensated Cirrhosis
|
N/A | |
Completed |
NCT02642432 -
A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 4, 5 or 6 Infection and Compensated Cirrhosis
|
Phase 3 | |
Completed |
NCT03656068 -
An Evaluation of the Safety and Efficacy of Nitazoxanide on Collagen Turnover in NASH Patients With Fibrosis
|
Phase 2 | |
Not yet recruiting |
NCT05357599 -
The Use of Endoscopic Ultrasound-Guided Portal Pressure Measurements to Guide Beta-Blocker Therapy in Patients With Compensated Cirrhosis
|
N/A | |
Not yet recruiting |
NCT06147518 -
To Compare the Safety and Efficacy of Dapagliflozin Plus Metformin Versus Sitagliptin Plus Metformin for Treatment of Diabetes in Patients With Compensated and Stable Decompensated Cirrhosis
|
N/A |